NM_014363.6:c.5826C>T
Variant names: 
Variant summary
Our verdict is Benign. The variant received -17 ACMG points: 0P and 17B. BP4_StrongBP6_Very_StrongBP7BS1
The NM_014363.6(SACS):c.5826C>T(p.Tyr1942Tyr) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000843 in 1,613,672 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
 Genomes: 𝑓 0.00013   (  1   hom.,  cov: 33) 
 Exomes 𝑓:  0.000079   (  0   hom.  ) 
Consequence
 SACS
NM_014363.6 synonymous
NM_014363.6 synonymous
Scores
 2
Clinical Significance
Conservation
 PhyloP100:  1.79  
Publications
0 publications found 
Genes affected
 SACS  (HGNC:10519):  (sacsin molecular chaperone) This gene encodes the sacsin protein, which includes a UbL domain at the N-terminus, a DnaJ domain, and a HEPN domain at the C-terminus. The gene is highly expressed in the central nervous system, also found in skin, skeletal muscles and at low levels in the pancreas. This gene includes a very large exon spanning more than 12.8 kb. Mutations in this gene result in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), a neurodegenerative disorder characterized by early-onset cerebellar ataxia with spasticity and peripheral neuropathy. The authors of a publication on the effects of siRNA-mediated sacsin knockdown concluded that sacsin protects against mutant ataxin-1 and suggest that "the large multi-domain sacsin protein is able to recruit Hsp70 chaperone action and has the potential to regulate the effects of other ataxia proteins" (Parfitt et al., PubMed: 19208651). A pseudogene associated with this gene is located on chromosome 11. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, May 2013] 
SACS Gene-Disease associations (from GenCC):
- Charlevoix-Saguenay spastic ataxiaInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, G2P, Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae), Myriad Women’s Health
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -17 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.65). 
BP6
Variant 13-23338050-G-A is Benign according to our data. Variant chr13-23338050-G-A is described in ClinVar as Benign. ClinVar VariationId is 458266.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. 
BP7
Synonymous conserved (PhyloP=1.79 with no splicing effect.
BS1
Variant frequency is greater than expected in population amr. GnomAd4 allele frequency = 0.000131 (20/152168) while in subpopulation AMR AF = 0.00131 (20/15272). AF 95% confidence interval is 0.000867. There are 1 homozygotes in GnomAd4. There are 7 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position passed quality control check. 
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes  0.000131  AC: 20AN: 152168Hom.:  1  Cov.: 33 show subpopulations 
GnomAD3 genomes 
 AF: 
AC: 
20
AN: 
152168
Hom.: 
Cov.: 
33
Gnomad AFR 
 AF: 
Gnomad AMI 
 AF: 
Gnomad AMR 
 AF: 
Gnomad ASJ 
 AF: 
Gnomad EAS 
 AF: 
Gnomad SAS 
 AF: 
Gnomad FIN 
 AF: 
Gnomad MID 
 AF: 
Gnomad NFE 
 AF: 
Gnomad OTH 
 AF: 
GnomAD2 exomes  AF:  0.000387  AC: 97AN: 250908 AF XY:  0.000295   show subpopulations 
GnomAD2 exomes 
 AF: 
AC: 
97
AN: 
250908
 AF XY: 
Gnomad AFR exome 
 AF: 
Gnomad AMR exome 
 AF: 
Gnomad ASJ exome 
 AF: 
Gnomad EAS exome 
 AF: 
Gnomad FIN exome 
 AF: 
Gnomad NFE exome 
 AF: 
Gnomad OTH exome 
 AF: 
GnomAD4 exome  AF:  0.0000794  AC: 116AN: 1461504Hom.:  0  Cov.: 36 AF XY:  0.0000646  AC XY: 47AN XY: 727046 show subpopulations 
GnomAD4 exome 
 AF: 
AC: 
116
AN: 
1461504
Hom.: 
Cov.: 
36
 AF XY: 
AC XY: 
47
AN XY: 
727046
show subpopulations 
African (AFR) 
 AF: 
AC: 
0
AN: 
33430
American (AMR) 
 AF: 
AC: 
111
AN: 
44676
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
0
AN: 
26120
East Asian (EAS) 
 AF: 
AC: 
0
AN: 
39698
South Asian (SAS) 
 AF: 
AC: 
0
AN: 
86232
European-Finnish (FIN) 
 AF: 
AC: 
0
AN: 
53384
Middle Eastern (MID) 
 AF: 
AC: 
0
AN: 
5766
European-Non Finnish (NFE) 
 AF: 
AC: 
1
AN: 
1111822
Other (OTH) 
 AF: 
AC: 
4
AN: 
60376
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.490 
Heterozygous variant carriers
 0 
 8 
 16 
 23 
 31 
 39 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Exome Het
Variant carriers
 0 
 4 
 8 
 12 
 16 
 20 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
GnomAD4 genome  0.000131  AC: 20AN: 152168Hom.:  1  Cov.: 33 AF XY:  0.0000942  AC XY: 7AN XY: 74334 show subpopulations 
GnomAD4 genome 
 AF: 
AC: 
20
AN: 
152168
Hom.: 
Cov.: 
33
 AF XY: 
AC XY: 
7
AN XY: 
74334
show subpopulations 
African (AFR) 
 AF: 
AC: 
0
AN: 
41448
American (AMR) 
 AF: 
AC: 
20
AN: 
15272
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
0
AN: 
3470
East Asian (EAS) 
 AF: 
AC: 
0
AN: 
5190
South Asian (SAS) 
 AF: 
AC: 
0
AN: 
4832
European-Finnish (FIN) 
 AF: 
AC: 
0
AN: 
10600
Middle Eastern (MID) 
 AF: 
AC: 
0
AN: 
316
European-Non Finnish (NFE) 
 AF: 
AC: 
0
AN: 
68036
Other (OTH) 
 AF: 
AC: 
0
AN: 
2092
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.506 
Heterozygous variant carriers
 0 
 1 
 3 
 4 
 6 
 7 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Genome Het
Variant carriers
 0 
 2 
 4 
 6 
 8 
 10 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
Alfa 
 AF: 
Hom.: 
Bravo 
 AF: 
ClinVar
Significance: Benign 
Submissions summary: Benign:3 
Revision: criteria provided, multiple submitters, no conflicts
LINK: link 
Submissions by phenotype
not specified    Benign:1 
Nov 03, 2020
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Spastic paraplegia    Benign:1 
Dec 16, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
not provided    Benign:1 
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
Computational scores
Source: 
Name
Calibrated prediction
Score
Prediction
 BayesDel_noAF 
 Benign 
 DANN 
 Benign 
 PhyloP100 
 RBP_binding_hub_radar 
 RBP_regulation_power_radar 
Splicing
Name
Calibrated prediction
Score
Prediction
 SpliceAI score (max) 
Details are displayed if max score is > 0.2
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at 
Publications
 You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.